Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of enoxaparin in patients with chronic kidney disease: safety considerations.

Literature DB >> 17973538

Use of enoxaparin in patients with chronic kidney disease: safety considerations.

Donald F Brophy¹, Domenic A Sica.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Anticoagulants
Enoxaparin

Year: 2007 PMID： 17973538 DOI： 10.2165/00002018-200730110-00001

Source DB: PubMed Journal: Drug Saf ISSN： 0114-5916 Impact factor: 5.606

× No keyword cloud information.

15 in total

1. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.

Authors: Jean-Sébastien Hulot; Gilles Montalescot; Philippe Lechat; Jean-Philippe Collet; Annick Ankri; Saïk Urien
Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875

2. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.

Authors: Donald F Brophy; Marcus E Carr; Erika J Martin; Jürgen Venitz; Todd W B Gehr
Journal: J Clin Pharmacol Date: 2006-08 Impact factor: 3.126

3. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.

Authors: D F Brophy; E J Martin; T W B Gehr; A M Best; K Paul; M E Carr
Journal: J Thromb Haemost Date: 2006-02 Impact factor: 5.824

4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Authors: Wendy Lim; Francesco Dentali; John W Eikelboom; Mark A Crowther
Journal: Ann Intern Med Date: 2006-05-02 Impact factor: 25.391

Review 5. Platelet dysfunction in renal failure.

Authors: Paola Boccardo; Giuseppe Remuzzi; Miriam Galbusera
Journal: Semin Thromb Hemost Date: 2004-10 Impact factor: 4.180

6. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Authors: E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald
Journal: Circulation Date: 1999-10-12 Impact factor: 29.690

7. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.

Authors: Jean Philippe Collet; Gilles Montalescot; Erika Fine; Jean Louis Golmard; Miles Dalby; Rémi Choussat; Annick Ankri; Raphaëlle Dumaine; Claude Lesty; Nicolas Vignolles; Daniel Thomas
Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094

Review 8. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors: M M Buckley; E M Sorkin
Journal: Drugs Date: 1992-09 Impact factor: 9.546

Use of enoxaparin in patients with chronic kidney disease: safety considerations.

1. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.

2. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.

3. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.

4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Review 5. Platelet dysfunction in renal failure.

6. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

7. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.

Review 8. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

9. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

10. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.

1. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

2. The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists.

Review 3. Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

4. Current awareness: pharmacoepidemiology and drug safety.